Psilocybin Dose-Response: What the Clinical Pharmacology Shows

About This Video

Understanding the dose-response relationship for psilocybin is essential for clinical trial design, harm reduction education, and individual decision-making — yet it is rarely explained in accessible terms. This Heffter Research Institute presentation covers the human pharmacology of psilocybin from a clinical pharmacology perspective, including absorption, metabolism, receptor occupancy, and the dose-subjective effect relationship.

Psilocybin is a prodrug: it has minimal pharmacological activity itself and must be converted by alkaline phosphatases in the gut and liver to psilocin, which crosses the blood-brain barrier and acts at 5-HT2A receptors. The conversion is rapid (15–30 minutes after oral administration) and nearly complete. This explains why onset of effects is typically 20–40 minutes after ingestion — and why absorption from an empty stomach is substantially faster than with food.

The dose-response curve is sigmoidal and highly individual-dependent. Body weight is a poor predictor of response — at equivalent mg/kg doses, people show enormous variability in subjective experience intensity. Sources of variability include receptor density, baseline serotonergic tone, CYP enzyme metabolism rates, prior psychedelic exposure, and psychological factors. Clinical dose ranges covered: 1mg inactive placebo, 10mg mild perceptual effects, 25mg the full therapeutic experience in most participants. Duration: peak at approximately 2 hours, resolution by 6–8 hours, neuroplasticity elevation persists 2–4 weeks.